

Michalis Lontos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1049307/publications.pdf>

Version: 2024-02-01

96
papers

4,783
citations

201385

27
h-index

98622

67
g-index

100
all docs

100
docs citations

100
times ranked

7501
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review. <i>Breast Care</i> , 2022, 17, 63-70.	0.8	6
2	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 117-118.	2.0	7
3	Molecular testing for prostate cancer in Greek patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 170-170.	0.8	0
4	Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. <i>Frontiers in Oncology</i> , 2022, 12, 847917.	1.3	12
5	Identification and Biopsy of Sentinel Lymph Node in Early-Stage Cervical Carcinoma: Diagnostic Accuracy and Clinical Utility. <i>Cureus</i> , 2022, 14, e23838.	0.2	0
6	Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100953.	0.3	1
7	“The emerging role of capivasertib in breast cancer” <i>Breast</i> , 2022, 63, 157-167.	0.9	20
8	DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?. <i>Biomedicines</i> , 2022, 10, 82.	1.4	7
9	Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature. <i>Supportive Care in Cancer</i> , 2022, , 1.	1.0	4
10	A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma. <i>Journal of Investigative Surgery</i> , 2022, , 1-2.	0.6	0
11	Advances in Gynecological Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6152.	1.8	1
12	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. <i>Cancers</i> , 2022, 14, 2796.	1.7	9
13	Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e212-e219.	1.1	39
14	The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review. <i>Breast Care</i> , 2021, 16, 6-15.	0.8	13
15	Clinical perspectives of BET inhibition in ovarian cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 237-249.	2.1	23
16	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. <i>Cancers</i> , 2021, 13, 763.	1.7	3
17	Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting. <i>Current Oncology</i> , 2021, 28, 1143-1152.	0.9	2
18	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. <i>Vaccines</i> , 2021, 9, 422.	2.1	8

#	ARTICLE	IF	CITATIONS
19	The systemic treatment of uterine leiomyosarcomas. <i>Medicine (United States)</i> , 2021, 100, e25309.	0.4	5
20	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 86.	6.9	31
21	Regulatory and Functional Involvement of Long Non-Coding RNAs in DNA Double-Strand Break Repair Mechanisms. <i>Cells</i> , 2021, 10, 1506.	1.8	16
22	Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?. <i>Frontiers in Oncology</i> , 2021, 11, 683057.	1.3	1
23	CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience. <i>Medical Sciences (Basel)</i> , 2021, 10, 10750.	1.3	0
24	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855.	0.8	183
25	MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment. <i>Cancers</i> , 2021, 13, 4114.	1.7	10
26	Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100826.	0.3	3
27	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.	0.9	15
28	Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. <i>Cancers</i> , 2021, 13, 465.	1.7	7
29	Pembrolizumab in endometrial cancer: Where we stand now (Review). <i>Oncology Letters</i> , 2021, 22, 821.	0.8	10
30	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021, 9, 1148.	2.1	10
31	The Role of Circular RNAs in DNA Damage Response and Repair. <i>Cancers</i> , 2021, 13, 5352.	1.7	9
32	How do different histologic components of mixed endometrial carcinomas affect prognosis? Does it really matter?. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2021, 42, 105-111.	0.3	1
33	Rare cancers are common: time to act. <i>Forum of Clinical Oncology</i> , 2021, 11, 1-2.	0.1	0
34	BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients. <i>Current Oncology</i> , 2021, 28, 4446-4456.	0.9	2
35	What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. <i>Current Oncology</i> , 2021, 28, 4862-4873.	0.9	0
36	The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 797505.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). <i>Current Oncology</i> , 2021, 28, 5266-5277.	0.9	1
38	The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies. <i>Cancers</i> , 2020, 12, 62.	1.7	20
39	Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer. <i>Case Reports in Oncology</i> , 2020, 13, 627-632.	0.3	8
40	Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100615.	0.3	7
41	Controversies in preoperative bowel preparation in gynecologic and gynecologic oncology surgery: a review of the literature. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1049-1061.	0.8	5
42	Response of an oncology unit in the midst of the COVID-19 outbreak. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1947-1952.	0.5	1
43	A Case Series of BCOR Sarcomas With a New Splice Variant of <i>BCOR/CCNB3</i> Fusion Gene. <i>In Vivo</i> , 2020, 34, 2947-2954.	0.6	7
44	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology</i> , The, 2020, 21, 1513-1525.	5.1	35
45	The emerging role of BET inhibitors in breast cancer. <i>Breast</i> , 2020, 53, 152-163.	0.9	31
46	Supportive medication in cancer during pregnancy. <i>BMC Pregnancy and Childbirth</i> , 2020, 20, 747.	0.9	3
47	Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2020, 157, 599-605.	0.6	5
48	<p>Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 141-146.	0.9	2
49	JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. <i>European Journal of Cancer</i> , 2020, 126, 125-135.	1.3	48
50	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1603-1603.	0.7	8
51	Cancer Patients and Oncology Clinical Practice in COVID-19 Pandemic. <i>Forum of Clinical Oncology</i> , 2020, 11, 1-2.	0.1	0
52	Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	0
53	Ewing's sarcoma of the cervix: A case report of an unusual diagnosis in pregnancy treated with surgery, adjuvant VIDE and radiotherapy. <i>Oncology Letters</i> , 2019, 17, 5529-5535.	0.8	7
54	Systemic therapy in cervical cancer: 30 years in review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 9-17.	2.0	119

#	ARTICLE	IF	CITATIONS
55	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019, 24, 1348-1355.	1.9	10
56	Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e360-e364.	0.9	9
57	Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. <i>Cancer Treatment Reviews</i> , 2019, 73, 54-61.	3.4	28
58	Unfolding Ariadne's thread in the scientific publications' labyrinth. <i>Forum of Clinical Oncology</i> , 2019, 9, 1-2.	0.1	0
59	Cyclin-dependent kinase (CDK) 4/6 inhibitors in oncology. <i>Forum of Clinical Oncology</i> , 2019, 10, 1-1.	0.1	0
60	Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>Annals of Oncology</i> , 2018, 29, 361-369.	0.6	57
61	The New Age of -omics in Urothelial Cancer – Re-wording Its Diagnosis and Treatment. <i>EBioMedicine</i> , 2018, 28, 43-50.	2.7	12
62	Panitumumab in combination with modified docetaxel/ cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group. <i>Annals of Gastroenterology</i> , 2018, 31, 698-704.	0.4	3
63	Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. <i>BMC Cancer</i> , 2018, 18, 1247.	1.1	29
64	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68.	0.6	44
65	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). <i>Annals of Translational Medicine</i> , 2018, 6, 144-144.	0.7	19
66	Treating ALK-positive non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 141-141.	0.7	23
67	Gefitinib: an "orphan" drug for non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 899-906.	0.5	2
68	Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. <i>World Journal of Urology</i> , 2017, 35, 411-419.	1.2	20
69	Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 405-413.	0.2	12
70	Prognostic factors for recurrence in early stage adult granulosa cell tumor of the ovary. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1031-1036.	0.8	29
71	The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. <i>PLoS ONE</i> , 2016, 11, e0156403.	1.1	22
72	DNA damage, tumor mutational load and their impact on immune responses against cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 264-264.	0.7	35

#	ARTICLE	IF	CITATIONS
73	Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 1837.	1.0	7
74	Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. <i>Cell Death and Differentiation</i> , 2014, 21, 998-1012.	5.0	254
75	Prognostic Significance of Cytoablative Nephrectomy in Patients With Synchronous Metastases From Renal Cell Carcinoma Treated With First-Line Sunitinib: A European Multiinstitutional Study. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 373-383.	0.9	39
76	The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. <i>Cell Death and Differentiation</i> , 2013, 20, 1485-1497.	5.0	57
77	Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. <i>Nature Cell Biology</i> , 2013, 15, 967-977.	4.6	113
78	Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 15885-15909.	1.8	105
79	TPL2 kinase is a suppressor of lung carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1470-9.	3.3	50
80	Detection of Herpes Simplex Virus-1 and -2 in Cardiac Myxomas. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-6.	3.0	7
81	The Tumor Suppressor Gene ARF as a Sensor of Oxidative Stress. <i>Current Molecular Medicine</i> , 2012, 12, 704-715.	0.6	19
82	Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. <i>Nature Cell Biology</i> , 2011, 13, 292-302.	4.6	294
83	Loss of p14 ^{ARF} confers resistance to heat shock- and oxidative stress-mediated cell death by upregulating β -catenin. <i>International Journal of Cancer</i> , 2011, 128, 1989-1995.	2.3	17
84	Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins. <i>Journal of Cell Biology</i> , 2011, 195, 1123-1140.	2.3	86
85	Increased expression of bFGF is associated with carotid atherosclerotic plaques instability engaging the NF- κ B pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2273-2280.	1.6	31
86	The roles of p27 ^{Kip1} and DNA damage signalling in the chemotherapy-induced delayed cell cycle checkpoint. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2264-2267.	1.6	11
87	Molecular Techniques in Surgical Research. , 2010, , 951-974.		0
88	Src-Induced Disassembly of Adherens Junctions Requires Localized Phosphorylation and Degradation of the Rac Activator Tiam1. <i>Molecular Cell</i> , 2009, 33, 639-653.	4.5	82
89	Modulation of the E2F1-Driven Cancer Cell Fate by the DNA Damage Response Machinery and Potential Novel E2F1 Targets in Osteosarcomas. <i>American Journal of Pathology</i> , 2009, 175, 376-391.	1.9	48
90	Mutant p53 Enhances Nuclear Factor κ B Activation by Tumor Necrosis Factor α in Cancer Cells. <i>Cancer Research</i> , 2007, 67, 2396-2401.	0.4	178

#	ARTICLE	IF	CITATIONS
91	Deregulated Overexpression of hCdt1 and hCdc6 Promotes Malignant Behavior. <i>Cancer Research</i> , 2007, 67, 10899-10909.	0.4	191
92	Evaluation of claspin as a proliferation marker in human cancer and normal tissues. <i>Journal of Pathology</i> , 2007, 211, 331-339.	2.1	29
93	Gene amplification is a relatively frequent event leading to <i>ZBTB7A</i> (<i>Pokemon</i>) overexpression in non-small cell lung cancer. <i>Journal of Pathology</i> , 2007, 213, 294-302.	2.1	57
94	Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. <i>Nature</i> , 2006, 444, 633-637.	13.7	1,777
95	Factors contributing to inappropriate ordering of tests in an academic medical department and the effect of an educational feedback strategy. <i>Postgraduate Medical Journal</i> , 2006, 82, 823-829.	0.9	200
96	Human Leukocyte Antigens as Genetic Markers in Greek Patients With Sporadic Pancreatic Cancer. <i>Pancreas</i> , 2004, 29, 41-44.	0.5	4